Figure 6.

lncZic2–BRG1–MARCKS/MARCKSL1 can be targeted for liver TIC elimination. A, 1 × 10⁶ primary cells were subcutaneously injected into BALB/c nude mice. When tumors were established (about 250 mm³), lncZic2 antisense oligo (ASO) and control antisense oligo were intratumorally injected every 2 days. One month later, tumors were obtained, and tumor weight was observed. Ctrl, control. B, 1 × 10⁶ lncZic2-overexpressing (oe) cells and control cells were subcutaneously injected into BALB/c nude mice, and tumor weight was examined 1 month later. C, 1 × 10⁶ primary cells were used for tumor propagation, and the indicated reagents were used for intratumoral injection. The tumors were weighted 1 month later. D, the indicated tumors were obtained, and MARCKS/MARCKSL1 expression levels were examined through immunohistochemistry. Scale bars = 100 μm. E, the indicated tumors were obtained, and CD133⁺ liver TICs were examined through FACS. n = 6 for each group, and the ratios of liver TICs were shown as means ± SD. FSC, forward scatter. Experiments were repeated at least three times. ***, p < 0.001 by t test.